BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 27919910)

  • 21. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic significance of
    Wang J; Sun K; Chen WM; Wang X; Li LD; Hao Y; Xu N; Jiang H; Xu LP; Wang Y; Zhang XH; Huang XJ; Jiang Q; Qin YZ
    Leuk Lymphoma; 2023 Mar; 64(3):698-706. PubMed ID: 36642937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
    Wells J; Jain N; Konopleva M
    Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients.
    Jain N; Lu X; Daver N; Thakral B; Wang SA; Konoplev S; Patel K; Kanagal-Shamanna R; Valentine M; Tang G; Pemmaraju N; Jorgensen J; Kebriaei P; Nunez CA; Wierda W; Jabbour E; Roberts KG; Mullighan CG; Kantarjian H; Konopleva M
    Haematologica; 2017 Dec; 102(12):e514-e517. PubMed ID: 28860345
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
    Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
    Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prognostic analysis of children with Philadelphia chromosome-like acute lymphoblastic leukemia common genes].
    Hu WD; Li B; Su SF; Liu YF; Liu W; Zhang WL; Zuo WL; Yu RH
    Zhonghua Er Ke Za Zhi; 2023 May; 61(5):446-452. PubMed ID: 37096265
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
    Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
    Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.
    Chiaretti S; Brugnoletti F; Messina M; Paoloni F; Fedullo AL; Piciocchi A; Elia L; Vitale A; Mauro E; Ferrara F; De Fabritiis P; Luppi M; Ronco F; De Propris MS; Raponi S; Kronnie GT; Vignetti M; Guarini A; Foà R
    Leuk Res; 2016 Feb; 41():36-42. PubMed ID: 26754556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
    Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
    Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
    Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of Philadelphia-like Pre-B Acute Lymphoblastic Leukemia: Experiences in Mexican Pediatric Patients.
    Martínez-Anaya D; Moreno-Lorenzana D; Reyes-León A; Juárez-Figueroa U; Dean M; Aguilar-Hernández MM; Rivera-Sánchez N; García-Islas J; Vieyra-Fuentes V; Zapata-Tarrés M; Juárez-Villegas L; Paredes-Aguilera R; Vega-Vega L; Rivera-Luna R; Juárez-Velázquez MDR; Pérez-Vera P
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia.
    Dou H; Chen X; Huang Y; Su Y; Lu L; Yu J; Yin Y; Bao L
    Genes Chromosomes Cancer; 2017 Feb; 56(2):135-146. PubMed ID: 27637012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
    Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
    Lu XT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
    Schmäh J; Fedders B; Panzer-Grümayer R; Fischer S; Zimmermann M; Dagdan E; Bens S; Schewe D; Moericke A; Alten J; Bleckmann K; Siebert R; Schrappe M; Stanulla M; Cario G
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28371317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.
    Ge Z; Gu Y; Zhao G; Li J; Chen B; Han Q; Guo X; Liu J; Li H; Yu MD; Olson J; Steffens S; Payne KJ; Song C; Dovat S
    Oncotarget; 2016 Aug; 7(31):49722-49732. PubMed ID: 27391346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.
    Buitenkamp TD; Pieters R; Gallimore NE; van der Veer A; Meijerink JP; Beverloo HB; Zimmermann M; de Haas V; Richards SM; Vora AJ; Mitchell CD; Russell LJ; Schwab C; Harrison CJ; Moorman AV; van den Heuvel-Eibrink MM; den Boer ML; Zwaan CM
    Leukemia; 2012 Oct; 26(10):2204-11. PubMed ID: 22441210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
    Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical Features and Prognosis of Acute Lymphoblastic Leukemia Children with P2RY8-CRLF2 Gene Rearrangement].
    Zheng YZ; LE SH; Zheng H; Hua XL; Chen ZS; Zheng L; Chen C; Li M; Cai CX; Yang JH; Chen YQ; Gao QL; Chen YY; Li J; Hu JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):311-315. PubMed ID: 33812392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.